312 related articles for article (PubMed ID: 19382527)
21. Treatment of therapy-resistant sarcoidosis with adalimumab.
Callejas-Rubio JL; Ortego-Centeno N; Lopez-Perez L; Benticuaga MN
Clin Rheumatol; 2006 Jul; 25(4):596-7. PubMed ID: 16247590
[TBL] [Abstract][Full Text] [Related]
22. Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study.
Lahmer T; Knopf A; Lanzl I; Heemann U; Thuermel K
Rheumatol Int; 2012 Aug; 32(8):2367-70. PubMed ID: 21644042
[TBL] [Abstract][Full Text] [Related]
23. Infliximab for treating sarcoidosis patients, Portuguese experience.
Aguiar M; Marçal N; Mendes AC; Bugalho de Almeida A
Rev Port Pneumol; 2011; 17(2):85-93. PubMed ID: 21477572
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
25. [Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].
Flamant M; Bourreille A
Rev Med Interne; 2007 Dec; 28(12):852-61. PubMed ID: 17628232
[TBL] [Abstract][Full Text] [Related]
26. Targeting the TNF-alpha pathway in sarcoidosis.
Antoniu SA
Expert Opin Ther Targets; 2010 Jan; 14(1):21-9. PubMed ID: 20001207
[TBL] [Abstract][Full Text] [Related]
27. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report.
Santos G; Sousa LE; João AM
An Bras Dermatol; 2013; 88(6 Suppl 1):26-8. PubMed ID: 24346872
[TBL] [Abstract][Full Text] [Related]
28. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
[TBL] [Abstract][Full Text] [Related]
29. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
30. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab.
Cruz BA; Reis DD; Araujo CA;
Rheumatol Int; 2007 Oct; 27(12):1181-3. PubMed ID: 17520259
[TBL] [Abstract][Full Text] [Related]
31. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis.
Rezaee M; Zangiabadian M; Soheili A; Calcagno TM; Rahmannia M; Dinparastisaleh R; Nasiri MJ; Mirsaeidi M
Eur J Intern Med; 2023 Mar; 109():42-49. PubMed ID: 36526497
[TBL] [Abstract][Full Text] [Related]
32. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis.
Wijnen PA; Cremers JP; Nelemans PJ; Erckens RJ; Hoitsma E; Jansen TL; Bekers O; Drent M
Eur Respir J; 2014 Jun; 43(6):1730-9. PubMed ID: 24558177
[TBL] [Abstract][Full Text] [Related]
33. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
35. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
[TBL] [Abstract][Full Text] [Related]
36. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
37. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
38. TNF blocker drugs used to fight inflammation go head-to-head. Adalimumab had highest treatment response and remission rates, etanercept has longest drug survival rates; infliximab placed third.
Duke Med Health News; 2010 Mar; 16(3):3. PubMed ID: 20461880
[No Abstract] [Full Text] [Related]
39. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
[TBL] [Abstract][Full Text] [Related]
40. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
